Cadence (neuromodulation system for epilepsy)

2023: Product Announcement

On May 17, 2023, Cadence Neuroscience announced the development of a new high-tech neuromodulation-based therapy method for the treatment of children and adults with focal drug-resistant epilepsy.

This disease is characterized by the presence of a limited and clearly localized focus of abnormal electrical activity in the cerebral cortex. The symptoms of focal epilepsy are determined by in which proportion of the brain excess activity occurs. These can be motor (motor), vegetative, tactile, taste, olfactory and other attacks. In this case, the patient may show a violation of perception of reality.

Neuromodulation instrument from Cadence Neuroscience

Cadence Neuroscience's solution is based on stimulation of the cerebral cortex. The system modulates epilepsy-related EEG biomarkers to suppress seizures. It is assumed that the new technology will be able to help a huge number of people around the world.

As part of the development of the project, Cadence Neuroscience announced a Series B funding round, during which $26 million was raised. The leading investor was the Angelini Lumira Biosciences fund. In addition, the funds came from F-Prime Capital, LivaNova USA, Angelini Ventures, Spectrum Financial Services and Mayo Clinic. The main investor in the Series A round, Jazz Venture Partners, also contributed. Under the terms of the support program, Gerry Brunk of Angelini Lumira Biosciences and Kevin Chu of F-Prime Capital joined the board of directors of Cadence Neuroscience.

We believe that the Cadence platform can become an important standard of care for drug-resistant epilepsy, as well as other intractable brain diseases, "said Paolo Di Giorgio, CEO of Angelini Ventures.[1]

Notes